02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
19:01 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Galmed raises $75M follow-on

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) raised $75 million through the sale of 5 million shares at $15 in a follow-on underwritten by Stifel, SunTrust Robinson Humphrey, Cantor Fitzgerald, Raymond James, Roth Capital Partners, Maxim Group and...
18:45 , Jun 20, 2018 |  BC Extra  |  Financial News

Galmed raises $75M follow-on

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) raised $75 million through the sale of 5 million shares at $15 in a follow-on underwritten by Stifel, SunTrust Robinson Humphrey, Cantor Fitzgerald, Raymond James, Roth Capital Partners, Maxim Group and...
20:41 , Jun 14, 2018 |  BC Week In Review  |  Clinical News

After NASH readout, Galmed looks to Phase III

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) said data from the Phase IIb ARREST trial showed that once-daily oral Aramchol arachidyl amino cholanoic acid led to disease improvements in patients with non-alcoholic steatohepatitis (NASH). Galmed said the data...
18:33 , Jun 12, 2018 |  BC Extra  |  Clinical News

After NASH readout, Galmed looks to Phase III

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) gained $10.54 (150%) to $17.59 on Tuesday after it said data from the Phase IIb ARREST trial showed that once-daily oral Aramchol arachidyl amino cholanoic acid led to disease improvements in...
19:40 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Galmed's Aramchol misses in Phase IIa for HIV-associated NAFLD

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) said Aramchol arachidyl amino cholanoic acid missed the primary endpoint in the Phase IIa ARRIVE trial to treat HIV-associated lipodystrophy and non-alcoholic fatty liver disease (NAFLD). The company said it has...
19:51 , Feb 14, 2018 |  BC Extra  |  Clinical News

Galmed falls on Phase IIa HIV-associated NAFLD miss

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was down $4.01 (42%) to $5.45 on Wednesday after reporting that Aramchol arachidyl amino cholanoic acid missed the primary endpoint in the Phase IIa ARRIVE trial to treat HIV-associated lipodystrophy and...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Aramchol arachidyl amino cholanoic acid: Phase IIa started

Galmed began the double-blind, placebo-controlled, U.S. Phase IIa ARRIVE trial to evaluate 600 mg oral Aramchol once daily for 12 weeks in up to 50 patients with HIV-associated lipodystrophy and NAFLD. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD),...
07:00 , Sep 3, 2015 |  BC Innovations  |  Targets & Mechanisms

Low-fat brain

While most of the focus in Alzheimer's disease is on slowing or stopping the degeneration of neurons, a team at the University of Montreal has found that one cause of the disease could lie in...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Galmed Pharmaceuticals, OWL deal

The companies partnered to develop a non-invasive, blood-based companion diagnostic for Aramchol arachidyl amino cholanoic acid to treat non-alcoholic steatohepatitis (NASH). Galmed is conducting the Phase IIb ARREST trial of the synthetic conjugate of cholic...